Momenta Pharmaceuticals Inc. (MNTA) announced Monday morning that it will present updated data from its Phase 1 trial of necuparanib in combination with nab-paclitaxel and gemcitabine in patients with advanced metastatic pancreatic cancer at the 2015 ASCO Annual Meeting.
Momenta Pharmaceuticals gapped up Monday and rose sharply during the first half hour of trade, before settling into a range. Shares finished with a gain of 1.27 at $21.12 on above average volume. The stock climbed past the upper end of a month and a half long trading range and set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News